Tumor gastroenteropancreático neuroendocrino — origen GI (carcinoide), bien diferenciado G1/G2
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DIS-GI-NET |
|---|---|
| Tipo | Enfermedad |
| Aliaces | Apéndice NETTumor carcinoide (meduva)GEP-NET (non-pancreatic)Tumor neuroendocrino GI (carcinoide)GI-NETCarcinoide ilealNET rectalNET del intestino delgadoГастроентеропанкреатична нейроендокринна пухлина — ШКТ походження (карциноїд), добре-диференційована G1/G2 |
| Situación | reviewed 2026-05-03 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-NCCN-NET-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8240/3 |
|---|---|
| icd_o_3_topography | ["C17", "C18", "C19", "C20", "C18.1"] |
| icd_10 | C17.9 |
| who_classification | WHO Classification of Digestive System Tumours 5th ed (2019): Well-differentiated neuroendocrine tumour of small intestine/appendix/colon/rectum G1/G2 |
Notas
GI-NET (non-pancreatic) is the most common NET overall. Midgut/ileal carcinoids are prototypical: indolent growth, somatostatin receptor expression (SSTR2+), liver/mesenteric metastases, carcinoid syndrome (serotonin-driven flushing + diarrhea). Grading per WHO 2019: G1 Ki67 <3%, G2 Ki67 3–20%. Carcinoid syndrome occurs when serotonin (and other mediators) bypass hepatic metabolism — typically with liver metastases or retroperitoneal disease. SSA (octreotide/lanreotide) are the foundation of treatment: (1) symptom control and (2) antiproliferative (CLARINET, PROMID). PRRT (¹⁷⁷Lu-DOTATATE; NETTER-1 trial, Strosberg NEJM 2017) is approved for SSTR2+ midgut NETs after SSA progression — pending KB SSTR biomarker scaffolding (deferred). Key trials: CLARINET (lanreotide, Caplin NEJM 2014), PROMID (octreotide LAR, Rinke JCO 2009), NETTER-1 (PRRT, Strosberg NEJM 2017).
Utilizado por
Algoritmos
ALGO-GI-NET-ADVANCED-1L- ALGO-GI-NET-ADVANCED-1LALGO-MEN1-CARRIER-SURVEILLANCE- ALGO-MEN1-CARRIER-SURVEILLANCE
Enfermedad
DIS-PNET- Tumor neuroendocrino pancreático (pNET), G1/G2 bien diferenciado
Indicación
IND-CHRONIC-ATROPHIC-GASTRITIS-PREVENTION-OBSERVATION- IND-CHRONIC-ATROPHIC-GASTRITIS-PREVENTION-OBSERVATIONIND-CHRONIC-ATROPHIC-GASTRITIS-PREVENTION-SURVEILLANCE- IND-CHRONIC-ATROPHIC-GASTRITIS-PREVENTION-SURVEILLANCEIND-GI-NET-ADVANCED-1L-LANREOTIDE- IND-GI-NET-ADVANCED-1L-LANREOTIDE
Cuestionarios
QUEST-GI-NET-1L-STUB- tumor neuroendocrino GI (carcinoide) - primera línea
Señal de alerta
RF-CHRONIC-ATROPHIC-GASTRITIS-PREVENTION- Gastritis atrófica crónica (GAC) — pérdida histológicamente confirmada de oxíntesis y/o antral...RF-MEN1-CONFIRMED-CARRIER- Se confirmó la variante patogénica de la línea germinal / patogénica probable en el gen MEN1 (menina).RF-MEN1-FAMILY-HISTORY-SUSPICION- Pedigree familiar sugestivo de neoplasia endocrina múltiple tipo 1 (MEN1, síndrome de Wermer)...RF-MEN4-CONFIRMED-CARRIER- Variante patógena de la línea germinal confirmada / patógena probable en CDKN1B (p27/Kip1) — Múltiple...RF-NET-CARCINOID-SYNDROME- Síndrome carcinoide activo en un paciente con GI-NET metastático o irresecable (u otro tipo de...RF-NET-HIGH-GRADE-G3- Well-differentiated or poorly-differentiated neuroendocrine tumor with Ki67 >20% (WHO 201...
Fuentes
SRC-CLARINET-CAPLIN-2014- Lanreotide en tumores neuroendocrinos metastásicos (CLARINET; fase III)SRC-NCCN-NET-2025- Tumores neuroendocrinos y adrenales de NCCN